Gary Nabel

Last updated
Gary J. Nabel
Alma mater Harvard University
Brigham and Women’s Hospital
Scientific career
Fields Virology, Immunology
Institutions Sanofi
National Institute of Allergy and Infectious Diseases
Brigham and Women's Hospital
Harvard Medical School
University of Michigan

Gary J. Nabel is an American virologist and immunologist who is President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts.

Contents

Family

Gary J. Nabel was born in Hartford, Connecticut and is married to Elizabeth Nabel. They have three children.[ citation needed ]

Education

Nabel completed his undergraduate, M.D., and Ph.D. studies at Harvard University (1975, 1980, and 1982, respectively). He completed his dissertation research in the laboratory of immunologist Harvey Cantor and then worked as a postdoctoral fellow in the laboratory of David Baltimore at the Whitehead Institute, studying regulation of HIV gene expression by the recently discovered NF-κB, a host transcription factor. [1] [2] He completed his Internal Medicine residency at Brigham and Women’s Hospital.

Career

Nabel joined the faculty of the University of Michigan in 1987, where he led a research lab focused on infectious diseases and cancer immunotherapy. Nabel was an investigator of the Howard Hughes Medical Institute until 1999, [3] working on transcriptional regulation of cell and viral gene expressions, as well as viral vectors in gene therapy. [4] He was the Sewell Professor of Internal Medicine and Biological Chemistry.

In 1999, Nabel was recruited to build a vaccine research program for the country at the National Institutes of Health in Washington, DC. He served as the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, NIH and senior investigator with tenure at the National Institute of Allergy and Infectious Diseases. At NIH, Nabel pioneered a renaissance in vaccine development through structure-based rational vaccine design. Nabel provided overall direction and scientific leadership of the basic, clinical, and translational research activities and guided development of novel vaccine strategies. This vaccine work spanned basic science to clinical trials, including more than 100 clinical studies in the United States, Europe, and Africa, including SARS, Chikungunya, universal influenza vaccines and Ebola vaccines eventually tested in Africa.

Nabel moved to Sanofi in 2012, and as chief scientific officer and senior vice president, he oversaw the Breakthrough Lab, which developed the first trispecific antibodies now in development for HIV. [5] He also provided oversight of the Sanofi global R&D research portfolio, helping to guide more than ten products a year into clinical efficacy trials and bringing numerous products to licensure.

Nabel is currently president and chief executive officer for ModeX Therapeutics in Natick, Massachusetts.

Biomedical research

Nabel discovered the first effective vaccine candidates for Ebola, Chikungunya and encephalitis viruses through his approach to rational design using molecular virology, structure and immunology. This work catalyzed a renaissance in the vaccine field and led to novel passive and active immune interventions for universal influenza, EBV, and AIDS. He is author of more than 450 scientific publications, and he holds 86 patents.

At the University of Michigan, Nabel’s basic research investigated gene transfer, [6] basic mechanisms of HIV gene regulation and NF-κB transcriptional control. [7] [8]

As founding director of NIH’s Vaccine Research Center, Nabel pioneered a renaissance in vaccine development through his rational approach to vaccine design. Understanding the molecular genetics and structure of viral replication, he discovered the first vaccine against Ebola, using gene-based immunization to completely protect against infection in non-human primates. [9] [10] This work provided the conceptual basis that served as a prototype for the VSV vaccine recently proven efficacious in humans. He developed the first Chikungunya virus vaccine effective in primates and advanced universal influenza vaccines of unprecedented breadth and potency. His rational approach to structure-based vaccine design led to elucidation of broadly protective human immune responses to HIV, [11] leading to the discovery of broadly neutralizing antibodies to the highly conserved CD4 binding site of HIV with his colleagues from the VRC. Recently, he created an innovative antibody platform, trispecific Abs, that show unprecedented anti-HIV breadth and potency. These antibodies have advanced into human trials.

Recognizing the threat of Ebola virus decades ago, he applied molecular immunology and virology analysis to identify genes critical to Ebola replication and assembly. Importantly, he showed that gene-based prime-boost immunization stimulates potent cellular and humoral immune responses and discovered the first protective vaccine for highly lethal Ebola virus in non-human primates, [12] defined its immune mechanism of protection, and guided its development and testing in Africa. His work has stimulated international progress against emerging pathogens, having advanced novel SARS [13] and pandemic influenza. [14] [15] vaccines into clinical trials in record time, while creating promising candidates for encephalitis viruses and EBV.

At NIH’s Vaccine Research Center, he also contributed seminal advances to vaccine science neutralizing antibodies against HIV, universal influenza, [16] Ebola, [17] Chikungunya, [18] and Epstein-Barr virus. [19] He led research on viral molecular biology, protein structure, and immunotherapy, which defined modes of immune escape and led to the discovery of the broadly neutralizing antibodies to the highly conserved CD4 binding site of HIV that are now in human efficacy trials in Africa. [20]

At Sanofi, Nabel developed a novel antibody platform that can recognize three targets in a single protein, trispecific antibodies, now under evaluation for the treatment and prevention of AIDS and cancer. [21] [22]

Nabel has also worked on EBV vaccine development for nearly a decade, since first sponsoring a meeting at the NIH’s Vaccine Research Center with the participation of the National Institute of Allergy and Infectious Disease and the National Cancer Institute. In collaboration with Jeffrey Cohen and NIAID, Nabel worked to apply structure-based design to the development of EBV vaccines and generated promising candidates

Awards

Nabel’s honors include the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology, the Health and Human Services Secretary’s Award for Distinguished Service, and the Geoffrey Beene Foundation Builders of Science Award from Research!America. He received an honorary degree from the University of London, as well as the U.S. Army Medical Department’s Order of Military Medical Merit. Nabel is an elected fellow of the Association of American Physicians, the American Academy of the Arts and Sciences, and the American Association for the Advancement of Science. Nabel was elected to the American Society for Clinical Investigation in 1992 and the National Academy of Medicine in 1998.

Nabel served as the Chair of Board of Directors for the Keystone Scientific Symposia from 2017 to 2019. He as a Council Delegate to the AAAS, Medical Sciences Section from 1997 to 2002, and served as the editor for the Journal of Virology from 1995 to 2005.

Related Research Articles

<span class="mw-page-title-main">Wild type</span> Phenotype of the typical form of a species as it occurs in nature

The wild type (WT) is the phenotype of the typical form of a species as it occurs in nature. Originally, the wild type was conceptualized as a product of the standard "normal" allele at a locus, in contrast to that produced by a non-standard, "mutant" allele. "Mutant" alleles can vary to a great extent, and even become the wild type if a genetic shift occurs within the population. Continued advancements in genetic mapping technologies have created a better understanding of how mutations occur and interact with other genes to alter phenotype. It is now appreciated that most or all gene loci exist in a variety of allelic forms, which vary in frequency throughout the geographic range of a species, and that a uniform wild type does not exist. In general, however, the most prevalent allele – i.e., the one with the highest gene frequency – is the one deemed wild type.

<span class="mw-page-title-main">Hemagglutinin (influenza)</span> Hemagglutinin of influenza virus

Influenza hemagglutinin (HA) or haemagglutinin[p] is a homotrimeric glycoprotein found on the surface of influenza viruses and is integral to its infectivity.

Virus-like particles (VLPs) are molecules that closely resemble viruses, but are non-infectious because they contain no viral genetic material. They can be naturally occurring or synthesized through the individual expression of viral structural proteins, which can then self assemble into the virus-like structure. Combinations of structural capsid proteins from different viruses can be used to create recombinant VLPs. Both in-vivo assembly and in-vitro assembly have been successfully shown to form virus-like particles. VLPs derived from the Hepatitis B virus (HBV) and composed of the small HBV derived surface antigen (HBsAg) were described in 1968 from patient sera. VLPs have been produced from components of a wide variety of virus families including Parvoviridae, Retroviridae, Flaviviridae, Paramyxoviridae and bacteriophages. VLPs can be produced in multiple cell culture systems including bacteria, mammalian cell lines, insect cell lines, yeast and plant cells.

<span class="mw-page-title-main">Epitope mapping</span> Identifying the binding site of an antibody on its target antigen

In immunology, epitope mapping is the process of experimentally identifying the binding site, or epitope, of an antibody on its target antigen. Identification and characterization of antibody binding sites aid in the discovery and development of new therapeutics, vaccines, and diagnostics. Epitope characterization can also help elucidate the binding mechanism of an antibody and can strengthen intellectual property (patent) protection. Experimental epitope mapping data can be incorporated into robust algorithms to facilitate in silico prediction of B-cell epitopes based on sequence and/or structural data.

<span class="mw-page-title-main">Envelope glycoprotein GP120</span> Glycoprotein exposed on the surface of the HIV virus

Envelope glycoprotein GP120 is a glycoprotein exposed on the surface of the HIV envelope. It was discovered by Professors Tun-Hou Lee and Myron "Max" Essex of the Harvard School of Public Health in 1988. The 120 in its name comes from its molecular weight of 120 kDa. Gp120 is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface receptors. These receptors are DC-SIGN, Heparan Sulfate Proteoglycan and a specific interaction with the CD4 receptor, particularly on helper T-cells. Binding to CD4 induces the start of a cascade of conformational changes in gp120 and gp41 that lead to the fusion of the viral membrane with the host cell membrane. Binding to CD4 is mainly electrostatic although there are van der Waals interactions and hydrogen bonds.

Antigenic variation or antigenic alteration refers to the mechanism by which an infectious agent such as a protozoan, bacterium or virus alters the proteins or carbohydrates on its surface and thus avoids a host immune response, making it one of the mechanisms of antigenic escape. It is related to phase variation. Antigenic variation not only enables the pathogen to avoid the immune response in its current host, but also allows re-infection of previously infected hosts. Immunity to re-infection is based on recognition of the antigens carried by the pathogen, which are "remembered" by the acquired immune response. If the pathogen's dominant antigen can be altered, the pathogen can then evade the host's acquired immune system. Antigenic variation can occur by altering a variety of surface molecules including proteins and carbohydrates. Antigenic variation can result from gene conversion, site-specific DNA inversions, hypermutation, or recombination of sequence cassettes. The result is that even a clonal population of pathogens expresses a heterogeneous phenotype. Many of the proteins known to show antigenic or phase variation are related to virulence.

<span class="mw-page-title-main">Antonio Lanzavecchia</span> Italian and Swiss immunologist

Antonio Lanzavecchia is an Italian and Swiss immunologist. As a fellow of Collegio Borromeo he obtained a degree with honors in Medicine in 1976 from the University of Pavia where he specialized in Pediatrics and Infectious Diseases. He is Head Human Immunology Program, Istituto Nazionale di Genetica Molecolare-INGM, Milan and SVP Senior research Fellow, Humabs/Vir Biotechnology, Bellinzona and San Francisco (USA). Since 2017, he is also Professor at the Faculty of Biomedical Sciences of the Università della Svizzera italiana (USI).

<span class="mw-page-title-main">Antibody-dependent enhancement</span> Antibodies rarely making an infection worse instead of better

Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, followed by its replication. The suboptimal antibodies can result from natural infection or from vaccination. ADE may cause enhanced respiratory disease, but is not limited to respiratory disease. It has been observed in HIV, RSV virus and Dengue virus and is monitored for in vaccine development.

Long-term nonprogressors (LTNPs), sometimes also called elite controllers, are individuals infected with HIV, who maintain a CD4 count greater than 500 without antiretroviral therapy with a detectable viral load. Many of these patients have been HIV positive for 30 years without progressing to the point of needing to take medication in order not to develop AIDS. They have been the subject of a great deal of research, since an understanding of their ability to control HIV infection may lead to the development of immune therapies or a therapeutic vaccine. The classification "Long-term non-progressor" is not permanent, because some patients in this category have gone on to develop AIDS.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

2F5 is a broadly neutralizing human monoclonal antibody (mAb) that has been shown to bind to and neutralize HIV-1 in vitro, making it a potential candidate for use in vaccine synthesis. 2F5 recognizes an epitope in the membrane-proximal external region (MPER) of HIV-1 gp41. 2F5 then binds to this epitope and its constant region interacts with the viral lipid membrane, which neutralizes the virus.

A neutralizing antibody (NAb) is an antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies are part of the humoral response of the adaptive immune system against viruses, intracellular bacteria and microbial toxin. By binding specifically to surface structures (antigen) on an infectious particle, neutralizing antibodies prevent the particle from interacting with its host cells it might infect and destroy.

<span class="mw-page-title-main">Universal flu vaccine</span> Vaccine that prevents infection from all strains of the flu

A universal flu vaccine is a flu vaccine that is effective against all influenza strains regardless of the virus sub type, antigenic drift or antigenic shift. Hence it should not require modification from year to year. As of 2021 no universal flu vaccine had been approved for general use, several were in development, and one was in clinical trial.

<span class="mw-page-title-main">Susan Zolla-Pazner</span> American research scientist

Susan Zolla-Pazner is an American research scientist who is a Professor of Medicine in the Division of Infectious Diseases and the Department of Microbiology at Mount Sinai School of Medicine and a guest investigator in the Laboratory of Molecular Immunology at The Rockefeller University, both in New York City. Zolla-Pazner's work has focused on how the immune system responds to the human immunodeficiency virus (HIV) and, in particular, how antibodies against the viral envelope develop in the course of infection.

A Zika virus vaccine is designed to prevent the symptoms and complications of Zika virus infection in humans. As Zika virus infection of pregnant women may result in congenital defects in the newborn, the vaccine will attempt to protect against congenital Zika syndrome during the current or any future outbreak. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The goal of a Zika virus vaccine is to produce specific antibodies against the Zika virus to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection.

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene. ISH has proven effective for the treatment of influenza, rabies related lyssavirus, hepatitis B, and the HIV virus. This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response. It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge. The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.

<span class="mw-page-title-main">Nelson Michael</span> American infectious disease researcher

Nelson L. Michael is an American infectious disease researcher. He has served for nearly 30 years in the United States Army and been directly involved with significant advancements in understanding the pathology of and vaccine development for diseases like HIV, Zika, Ebola and more. Much of his career has been spent at the Walter Reed Army Institute of Research.

<span class="mw-page-title-main">Nancy Sullivan (biologist)</span> American cell biologist

Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.

<span class="mw-page-title-main">Viral vector vaccine</span> Type of vaccine

A viral vector vaccine is a vaccine that uses a viral vector to deliver genetic material (DNA) that can be transcribed by the recipient's host cells as mRNA coding for a desired protein, or antigen, to elicit an immune response. As of April 2021, six viral vector vaccines, four COVID-19 vaccines and two Ebola vaccines, have been authorized for use in humans.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

References

Notes

  1. ↑ Nabel, Gary; Baltimore, David (1987-04-22). "An inducible transcription factor activates expression of human immunodeficiency virus in T cells". Nature. 326 (6114): 711–713. doi:10.1038/326711a0. ISSN 0028-0836. PMID   3031512. S2CID 4317942.
  2. ↑ Osborn, L.; Kunkel, S.; Nabel, G. J. (1989-04-01). "Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B". Proceedings of the National Academy of Sciences. 86 (7): 2336–2340. doi:10.1073/pnas.86.7.2336. ISSN 0027-8424. PMC 286907. PMID   2494664.
  3. ↑ Dolgin, Elie (2013-03-06). "Straight talk with Gary Nabel". Nature Medicine. 19 (3): 256. doi:10.1038/nm0313-256. ISSN 1078-8956. PMID   23467227. S2CID 205377266.
  4. ↑ Nabel, G. J.; Nabel, E. G.; Yang, Z. Y.; Fox, B. A.; Plautz, G. E.; Gao, X.; Huang, L.; Shu, S.; Gordon, D.; Chang, A. E. (1993-12-01). "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans". Proceedings of the National Academy of Sciences. 90 (23): 11307–
  5. ↑ Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8. PMID 20616233; PMCID: PMC2965066.
  6. ↑ Nabel, G. J.; Nabel, E. G.; Yang, Z. Y.; Fox, B. A.; Plautz, G. E.; Gao, X.; Huang, L.; Shu, S.; Gordon, D.; Chang, A. E. (1993-12-01). "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans". Proceedings of the National Academy of Sciences. 90 (23): 11307–11311. doi:10.1073/pnas.90.23.11307. ISSN 0027-8424. PMC 47971. PMID   8248244.
  7. ↑ 5. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8. PMID 20616233; PMCID: PMC2965066.
  8. ↑ 6. Branswell, Helen (2016-03-17). "Sanofi science chief says it's to time 'think big' about Zika". Retrieved 2017-04-03.
  9. ↑ Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nature Med. 4(1):37-42.
  10. ↑ Sullivan N, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventative vaccine for Ebola virus infection in primates. Nature 408(6812):605-609.
  11. ↑ Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang S-H, Yang X, Zhang M- Y, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445(7129):732-7.
  12. ↑ Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB, Reimann KA, Bao S, Rao S, Roederer M, Jahrling PB, Koup RA, Nabel GJ. CD8(+) cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17(9):1128-1131.
  13. ↑ Yang Z-Y, Kong W-P, Huang Y, Roberts A, Murphy B, Subbarao K, Nabel GJ. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428(6982):561-564.
  14. ↑ Kong W-P, Hood C, Yang Z-Y, Wei C-J, Xu L, Garcia-Sastre A, Tumpey TM, Nabel GJ. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U.S.A. 103(43):15987- 15991.
  15. ↑ Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, Anderson H, Rao S, Tumpey TM, Yang Z-Y, Nabel GJ. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995):1060-1064.
  16. ↑ Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, Rao SS, Kong WP, Wang L, Nabel GJ. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499(7456):102-6.
  17. ↑ Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang Z-Y, Roederer M, Koup RA, Jahrling PB, Nabel GJ. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949):681-684.
  18. ↑ Akahata W, Yang Z-Y, Andersen H, Sun S, Holdaway HA, Kong W-P, Lewis MG, Higgs S, Rossman MG, Rao S, Nabel GJ. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16(3):334-338.
  19. ↑ Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, Yamamoto T, Narpala S, Todd JP, Rao SS, McDermott AB, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ, Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell.162(5):1090-1100.
  20. ↑ 7. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med. 6(243):243ra88, 2014.
  21. ↑ 8. Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, Cortez-Retamozo V, Ospina B, Posternak V, Ulinski G, Piepenhagen P, Francesconi E, El-Murr N, Beil C, Kirby P, Li A, Fretland J, Vicente R, Deng GJ, Dabdoubi T, Cameron B, Bertrand T, Ferrari P, Pouzieux S, Lemoine C, Prades C, Park A, Qiu HW, Song ZL, Zhang BL, Sun FX, Chiron M, Rao S, Radošević R, Yang Z-Y & Nabel GJ. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer 2019. doi:10.1038/s43018-019-0004-z.
  22. ↑ 9. Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Kwon YD, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O'Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017 Oct 6;358(6359):85-90. doi: 10.1126/science.aan8630. Epub 2017 Sep 20. PMID 28931639; PMCID: PMC5978417.

Selected publications

See Google Scholar for citation information.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.